What we do

Biotica Bio sells three productized systems for science-based biotech. Each has a named method, a tangible artifact, and a clear scope. Evidence from the Open Targets Platform and other public sources is used where applicable—reproducible, traceable, and updatable.

Why teams buy this

Pain	What you get
Decisions drown in screenshots	One structured map (targets, diseases, drugs, trade-offs) you can reuse for IC, BD, and portfolio review—not a one-off PDF.
The right people cannot find or trust the story	An implemented discoverability layer: coherent entities, narrative, and technical surfaces—not a generic “SEO project.”
Financing options feel binary (raise or stall)	A capital pathways matrix: plausible non-dilutive, partnership, and structured paths with comparables and readiness gaps—not pitch-deck optimism.

Together, the three offers answer: where to play, how you show up, and what financing shapes fit—with scope and independence (we do not invest).

Illustrative deliverable thread: inter-alpha inhibitor proteins (IaIP)

The following treats inter-alpha inhibitor proteins (IaIP) as a proposed blood-derived or recombinant protein therapeutic (administered as a product), not merely “a target family.” Public biology still routes through entities such as ITIH1–ITIH4 (inter-alpha-trypsin inhibitor heavy chains) and the broader IaIP / ITI complex story in the literature. Illustrative only: not a client engagement, not a clinical or commercial claim, and real work uses your CMC path, indications, and comparators.

How Open Targets and Orange Book show up (same vignette)

Layer	What we would use it for here
Open Targets	Indication rationale: target–disease associations and genetics involving ITIH-linked biology for candidate indications you name. Competitive landscape: approved drugs and clinical candidates touching the same pathways or adjacent mechanisms (protease–inhibitor biology, complement- and acute-phase–adjacent context where OT has edges—not “IaIP as a single marketed drug entity”). Modality density: how crowded indications are for biologics / protein therapeutics vs small molecules in OT’s drug and evidence slices.
FDA Orange Book	Listed approved drug products that serve as commercial precedent where they overlap your scoping question—typically ingredient / route / formulation-class and patent / exclusivity context for products that appear in OB. Honest scope note: many plasma-derived and recombinant biologic blood products are primarily documented outside the classic Orange Book NDA table (e.g. BLA / biologics licensing landscape). A real map still runs OB for relevant listed comparators (e.g. overlapping injectable / systemic protein precedent where listed) and states where OB is thin, so IC does not confuse “no OB row” with “no competition.”

Layer

What we would use it for here

Open Targets

Indication rationale: target–disease associations and genetics involving ITIH-linked biology for candidate indications you name. Competitive landscape: approved drugs and clinical candidates touching the same pathways or adjacent mechanisms (protease–inhibitor biology, complement- and acute-phase–adjacent context where OT has edges—not “IaIP as a single marketed drug entity”). Modality density: how crowded indications are for biologics / protein therapeutics vs small molecules in OT’s drug and evidence slices.

FDA Orange Book

Listed approved drug products that serve as commercial precedent where they overlap your scoping question—typically ingredient / route / formulation-class and patent / exclusivity context for products that appear in OB. Honest scope note: many plasma-derived and recombinant biologic blood products are primarily documented outside the classic Orange Book NDA table (e.g. BLA / biologics licensing landscape). A real map still runs OB for relevant listed comparators (e.g. overlapping injectable / systemic protein precedent where listed) and states where OB is thin, so IC does not confuse “no OB row” with “no competition.”

Portfolio Intelligence → Biotica Opportunity Map

Decision question (example): For an IaIP blood product in indication set X, where is public biology supportive vs noisy, and where is approved-product precedent (OB-listed or not) crowded vs differentiated?
Map contents (example): Normalized ITIH / disease / drug entities from OT; evidence summaries (association, known drugs, trials-linked candidates where OT surfaces them); OB pulls scoped to listed products that matter to your route, indication, and reimbursement narrative; explicit “OB vs BLA precedent” notes for blood product programs.
What you hold: A structured opportunity map + executive synthesis—same object, IC- or BD-ready views.

Visibility & Narrative → Biotica Discoverability Layer

Problem (example): The story mixes “IaIP therapeutic”, ITIH gene names, and plasma-derived vs recombinant positioning—so investors see target slides where they expect product / CMC clarity.
Layer contents (example): Product-first naming (blood product / protein therapeutic) tied to OT entity labels where you cite biology; schema and copy that distinguish mechanistic rationale (OT) from regulatory class (blood product path); OB-linked claims only where listed products support the sentence.
What you hold: A spec + prioritized backlog so science (OT) and commercial precedent language (OB where valid) line up on the site and deck-adjacent surfaces.

Strategic Capital Options → Biotica Capital Pathways Matrix

Context (example): A company advancing an IaIP blood product faces CMC-heavy spend and partner-dependent plasma or recombinant scale-up.
Matrix contents (example): Paths where comparables include fractionation / plasma supply deals, royalty-style partnerships, regional licensing, and non-dilutive instruments; readiness gaps call out lot consistency, supply chain, and IP—with OT/OB-backed market narrative feeding which paths are credible to discuss with which counterparties.
What you hold: A matrix + executive memo—trade-offs explicit, not transactional advice.

Contact with your real entities; we scope to your question, not this illustration.

1. Portfolio Intelligence System

For: Funds, CEOs, BD teams, portfolio functions.
Method: Biotica Opportunity Mapping Method.
Artifact: Biotica Opportunity Map (structured intelligence + executive outputs).
Includes: Asset and indication framing, competitive and whitespace views, partner target lists, diligence-style synthesis. Optional structure-informed layer (Open Targets + Orange Book + AlphaFold-class reads) as one fused package—Structure-informed diligence.

Evidence (pragmatic): Grounded in public layers when scoped—typically Open Targets for biology and competitive landscape; Orange Book when approved-drug precedent matters. Details: Evidence and tools.

Portfolio Intelligence System →

2. Visibility & Narrative System

For: Startups and portfolio companies.
Method: Biotica Discoverability Infrastructure Method.
Artifact: Biotica Discoverability Layer (implemented narrative and technical discoverability—not “SEO” as the headline).
Includes: Entity and narrative audits, authority footprint, structured presence, prioritized backlog.

Visibility & Narrative System →

3. Strategic Capital Options System

For: Later-stage or financing-stressed companies (often after portfolio framing is clear).
Method: Biotica Strategic Capital Pathways Method.
Artifact: Biotica Capital Pathways Matrix (options, comparables, readiness gaps).
Includes: Non-dilutive paths, licensing and partnering patterns, structured financing landscape—scoped, not advisory banking.

Strategic Capital Options System →

Engagement

All engagements are scoped and confidential. We do not invest, so there is no conflict of interest.

Typical deliverable shape

Portfolio Intelligence — Structured opportunity map + executive brief (5–10 pages typical) + methods appendix when evidence-backed runs apply.
Visibility & Narrative — Discoverability layer spec + prioritized implementation backlog.
Strategic Capital Options — Capital pathways matrix + executive memo.

Typical timeline

Scoping call: 30–45 minutes.
Proposal: 1–2 business days after scoping.
Delivery: Depends on entities and depth; quoted in the proposal.

For startups → · For investors → · Contact / scoping →

Our work is for strategic and due-diligence use only; it does not constitute regulatory, medical, or investment advice.